Chilco River Holdings Enters Premium Alcohol Beverage Sector, Targets Strategic Acquisitions to Accelerate Growth
Chatsworth, California--(Newsfile Corp. - May 29, 2025) - Chilco River Holdings, Inc. (OTC Pink: CRVH) ('Chilco' or the 'Company'), a rising force in brand acceleration, is thrilled to announce a transformative leap into the booming premium alcoholic beverage industry. This bold pivot marks the beginning of an ambitious growth strategy centered on acquiring standout brands and building a powerhouse portfolio in one of the most dynamic consumer markets.
The company is currently engaged in advanced negotiations with multiple acquisition targets including innovative upstarts and established premium labels. Chilco is positioning itself at the forefront of a surging industry driven by demand for craft spirits, ready-to-drink cocktails (RTDs), and luxury lifestyle beverages.
'The premium beverage space is exploding with opportunity,' stated, Chief Executive Officer, William Lovett. 'Our entry into this market is a game-changer, and we're already in deep discussions with brands that we believe can supercharge our trajectory and deliver lasting value to our shareholders.'
As part of this strategic realignment, the Company has formally canceled prior agreements with Leuffer Desarrollos SA de CV, American Hemp Brands, Inc., and L Myers Associates. These transactions were never consummated and no longer reflect the Company's core business objectives. This provides a fresh start and allows Chilco to dedicate full resources and strategic efforts toward the premium alcohol sector.
'This marks a clean slate and a bold new direction for Chilco,' continued Lovett. 'The premium beverage space is full of energy and opportunity, and we are excited to dive in. With the right strategy and execution, we believe we can build something truly impactful for our shareholders.'
In parallel with its renewed business direction, Chilco is proud to announce it has achieved Pink Current Information status with OTC Markets. This milestone not only underscores the Company's commitment to transparency but also unlocks powerful new levers for growth, including M&A activity, capital raising, and the onboarding of top-tier leadership.
With a clear vision and renewed focus, Chilco River Holdings is moving forward with determination and purpose. The Company is committed to transparency, disciplined execution, and consistent communication with shareholders. As it enters the premium alcohol space, Chilco is well-positioned to seize new opportunities and build lasting value in one of today's most dynamic markets.
About Chilco River Holdings, Inc.
Chilco River Holdings is a U.S.-based brand accelerator focused on identifying and acquiring premium consumer products with high-growth potential. The Company is currently targeting acquisitions in the premium alcohol beverage sector, including spirits, and ready-to-drink brands.
For more information, please contact:
Investor Relations
Chilco River Holdings, Inc.
Email: [email protected]
Website: www.chilcoriver.com
Forward-Looking Statements:
This press release contains forward-looking statements, including statements regarding the Company's strategic direction, acquisition plans, and anticipated growth. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially due to factors such as market conditions, due diligence outcomes, and regulatory approvals. Chilco River Holdings undertakes no obligation to update these statements, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253741
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Bull of the Day: Flotek Industries (FTK)
Flotek Industries (FTK) is a Zack Rank #1 (Strong Buy) that delivers sustainable chemistry solutions and real-time data analytics to clients across the energy and industrial sectors. The stock has surged to multi-year highs after a strong earnings report. Investors are starting to notice this relative strength in a sector that has been weak so far in 2025. Flotek Industries, Inc. is a Houston-based technology company that operates through two core segments: Chemistry Technologies (CT) and Data Analytics (DA). Its Chemistry Technologies division formulates and supplies environmentally conscious specialty chemicals designed to improve the efficiency and profitability of oil and gas production. These green chemistries are tailored to support a broad range of energy producers, including those in oil, gas, geothermal, and alternative energy. The Data Analytics segment complements Flotek's chemistry business by providing real-time measurement and insight tools that allow customers to monitor and optimize their operations while reducing emissions and carbon intensity. The company is valued at $450 million and has a Forward PE of 30. The stock has Zacks Style Scores of 'A' in Growth but 'D' in Value. Flotek reported a strong first quarter, delivering earnings of $0.17 per share, or a 183% EPS surprise to the upside. Revenue came in at $55.4 million, a 37% year-over-year increase. Both segments helped the quarter, with chemistry revenue up 36% and data analytics jumping 57%. Gross margin reached 23%, and net income rose 244%. Adjusted EBITDA more than doubled to $7.8 million, marking the fifth consecutive quarter of growth. The company guided full-year 2025 revenue to $200–210 million (vs. $203 million expected) and adjusted EBITDA of $34–39 million. At the midpoint, that implies 128% growth in both metrics, with EBITDA margin expected to expand to 17%, up from 11% in 2024. Flotek Industries, Inc. price-eps-surprise | Flotek Industries, Inc. Quote Flotek continues to scale its data analytics business rapidly, underpinned by its April acquisition of 30 gas monitoring and dual-fuel optimization assets tied to a $160 million multi-year contract. That deal is expected to generate over $20 million in annual operating income and push fixed-fee DAS revenue above $27 million in 2026. The stock surged after the earnings report, moving from the $8 area to $16 is just over a week. There has been about a month of consolidation since, but the stock remains near its recent post-earnings highs. Looking at analyst estimates, there is little movement on the short-term timeframe, but upside when looking down the road. For the current quarter, estimates have been lowered over the last 30 days from $0.11 to $0.10. For next quarter there have been no adjustments. For the current year we see numbers going higher over the last 90 days, moving from $0.43 to $0.53, or 23%. For next year there has been a move higher in estimates in just the last 30 days. Numbers have been taken from $0.58 to $0.67, or 15%. The stock has experienced a big move over the last month, more than doubling from the pre-earnings levels. A decade ago, the stock was at much higher levels, and after being left for dead in 2024 is back on the rise. Looking at the long-term chart, the downward trend is clearly broken. The stock has short-term room to the 2020 highs around $19, but investors would be better off waiting for pullbacks, rather than chasing. Let's look at some moving averages where bulls should be watching for support. 21-day: $14.60 50-day: $10.40 200-day: $8.00 Fibonacci Support levels reside at $11.40(50%) and $10.30 (61.8%). Flotek Industries has emerged as a standout in the energy sector, combining strong earnings momentum with a compelling growth story centered on green chemistry and real-time data analytics. The recent price surge reflects investor enthusiasm, but the technical setup suggests that pullbacks to key support levels may offer better entry points for long-term buyers. As energy markets remain volatile and capital flows shift toward differentiated tech-enabled solutions, Flotek's integrated platform and strategic growth initiatives could help it outperform peers. The stock's strong Zacks Rank, paired with bullish revisions and renewed institutional attention, reinforces the bullish case. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Flotek Industries, Inc. (FTK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Burlington, Massachusetts--(Newsfile Corp. - June 11, 2025) - Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented preclinical data on its lead program for LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. Results of multiple in vitro and in vivo studies in mice and in non-human primates (NHPs) demonstrated that LFD-200 achieves targeted and sustained delivery of its GC payload to immune cells, resulting in efficacy without systemic toxicity. These data were presented at the European Alliance of Associations for Rheumatology (EULAR) meeting in Barcelona. To view the full announcement, including downloadable images, bios, and more, click here. Click image above to view full announcement. About Lifordi Lifordi Immunotherapeutics, Inc. is leading the way in leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company's lead ADC, LFD-200, has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit Contacts: Theresa McNeely tmcneely@ Source: Lifordi To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
38 minutes ago
- Miami Herald
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies Inc. Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact: Avant Technologies SOURCE: Avant Solutions
